CYP17A1 and prostate carcinoma: In contrast, abiraterone acetate has been developed to selectively and irreversibly inhibit the CYP17 enzyme (17α-hydroxylase and C17,20-lyase) [30] and demonstrated significant antitumor activities against prostate cancer in phase I/II clinical trials [31, 32].